References
- Adams R. 1942. Marihuana: Harvey Lecture, February 19, 1942. Bull N Y Acad Med. 18(11):705–730.
- Bergamaschi MM, Queiroz RH, Chagas MH, de Oliveira DC, De Martinis BS, Kapczinski F, Quevedo J, Roesler R, Schröder N, Nardi AE, et al. 2011. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naïve social phobia patients. Neuropsychopharmacology. 36(6):1219–1226. doi:10.1038/npp.2011.6.
- Bonn-Miller MO, Loflin MJE, Thomas BF, Marcu JP, Hyke T, Vandrey R. 2017. Labeling accuracy of cannabidiol extracts sold online. JAMA. 318(17):1708–1709. doi:10.1001/jama.2017.11909.
- Callaway JC, Pate DW. 2009. Hempseed oil. In: Moreau RA, Kamal-Eldin A, editors. Gourmet and health-promoting specialty oils. Vienna: AOCS Press. p. 185–213.
- Cappelletto P, Brizzi M, Mongardini F, Barberi B, Sannibale M, Nenci G, Poli M, Corsi G, Grassi G, Pasini P, et al. 2001. Italy-grown hemp: yield, composition and cannabinoid content. Ind Crops Prod. 13(2):101–113. doi:10.1016/S0926-6690(00)00057-1.
- Commission on Narcotic Drugs. 2020. Compilation of all questions and answers on the WHO recommendations on cannabis and cannabis-related substances raised during the fourth and fifth intersessional meeting of the Commission at its sixty-second session. p. 53–56. https://www.unodc.org/documents/commissions/CND/CND_Sessions/CND_63/CRPs/ECN72020_CRP4_V2000845.pdf. Document No: E/CN.7/2020/CRP.4. Accessed 17 July 2020.
- Committee for Medicinal Products for Human Use (CHMP). 2019. International non-proprietary name: cannabidiol. Assessment report “Epidyolex.” p. 154–179. Assessment report. EMA/458106/2019. Accessed 17 July 2020
- Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. 2019. Scoping paper on the potential adverse effects of CBD products. TOX/2019/32. p. 1–52. https://cot.food.gov.uk/sites/default/files/tox2019-32.pdf. Accessed 17 July 2020
- Committee on Toxicity of Chemicals in Food, Consumer Products and the Environment. 2020. CBD update. TOX/2020/02. p. 1–33. https://cot.food.gov.uk/sites/default/files/tox202002cbd.pdf. Accessed 17 July 2020
- Cowen Research. 2019. Cowen’s collective view of CBD. https://www.cowen.com/reports/cowen-collective-view-of-cbd/. Accessed 17 July 2020
- Crippa JA, Derenusson GN, Ferrari TB, Wichert-Ana L, Duran FL, Martin-Santos R, Simões MV, Bhattacharyya S, Fusar-Poli P, Atakan Z, et al. 2011. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 25(1):121–130. doi:10.1177/0269881110379283.
- Department of Health, Therapeutic Goods Administration. 2020. Australia, safety of low dose cannabidiol. Version 1.0, April. https://www.tga.gov.au/sites/default/files/review-safety-low-dose-cannabidiol.pdf.
- Drugs and Firearms Licensing—Crime, Policing and Fire Group. (2018). Home office drug licensing factsheet—Cannabis, CBD and other cannabinoids. Version 1.3. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/757786/factsheet-cannabis-cbd-and-cannabinoids-v1-3-2018.pdf.
- Ellis GM, Jr, Mann MA, Judson BA, Schramm NT, Tashchian A. 1985. Excretion patterns of cannabinoid metabolites after last use in a group of chronic users. Clin Pharmacol Ther. 38(5):572–578. doi:10.1038/clpt.1985.226.
- EU Regulation. 1307/2013. No 1307/2013 of the European Parliament and of the Council of 17 December 2013 establishing rules for direct payments to farmers under support schemes within the framework of the common agricultural policy and repealing Council Regulation (EC) No 637/2008 and Council Regulation (EC) No 73/2009. Off J Eur Union, 347/608.
- European Commission—Health & Consumer Protection Directorate-General. 2001. ARfD as defined at 1.3. https://ec.europa.eu/food/sites/food/files/plant/docs/pesticides_ppp_app-proc_guide_tox_acute-ref-dose.pdf.
- European Commission. 2018. Draft regulation laying down the definition of maximum levels of tetrahydrocannabinol (THC) in food. Notification number: 2018/546/I (Italy). https://ec.europa.eu/growth/tools-databases/tris/en/index.cfm/search/?trisaction=search.detail&year=2018&num=546&mLang=EN.
- European Food Safety Authority (EFSA). 2011. Scientific opinion on the safety of hemp (Cannabis genus) for use as animal feed. EFSA J. 9(3). doi:10.2903/j.efsa.2011.2011
- European Food Safety Authority (EFSA). 2015. Scientific opinion on the risks for human health related to the presence of tetrahydrocannabinol (THC) in milk and other food of animal origin. EFSA J. 13(6):4141.
- European Food Safety Authority. 2020. Acute human exposure assessment to tetrahydrocannabinol (Δ9‐THC). EFSA J. 18(1):5953.
- European Industrial Hemp Association (EIHA). 2018. Cannabis sativa L. as a traditional food source. Presentation to the Novel Foods Working Group. 16th October. http://eiha.org/media/2019/01/18-10-16_NF-WG-EIHA-Presentation-Released-final.pdf.
- European Medicines Agency. 2016. Orphan designation: Delta-9-tetrahydrocannabinol and cannabidiol from extracts of the Cannabis sativa L. plant for the treatment glioma. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/orphans/2016/04/human_orphan_001722.jsp&mid=WC0b01ac058001d12b.
- European Medicines Agency. 2019a. Date of issue of marketing authorisation valid throughout the European Union: 19/09/2019. Marketing authorisation holder: GW Pharma (International) B.V. https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex.
- European Medicines Agency. 2019b. Epidyolex. https://www.ema.europa.eu/en/medicines/human/EPAR/epidyolex#authorisation-details-section.
- Food Standards Agency. 2020. Cannabidiol (CBD): business guidance on cannabidiol (CBD) as a novel food. https://www.food.gov.uk/business-guidance/cannabidiol-cbd.
- Food Standards Agency. Application for consultation to determine the status of a novel food, pursuant to Article 4(2). CBD Isolate. https://ec.europa.eu/food/sites/food/files/safety/docs/novel-food_consult-status_cbd-isolate_uk-fsa.pdf. Accessed17 July 2020.
- Hanuš LO, Meyer SM, Muñoz E, Taglialatela-Scafati O, Appendino G. 2016. Phytocannabinoids: a unified critical inventory. Nat Prod Rep. 33(12):1357–1392. doi:10.1039/c6np00074f.
- Hawksworth G, McArdle K. 2004. Metabolism and pharmacokinetics of cannabinoids. The medicinal uses of cannabis and cannabinoids. London (UK): Pharmaceutical Press. p. 205–228.
- Hazekamp A, Epifanova S. 2017. Grote variatie in samenstelling cannabisolie noopt tot regels. Pharm Weekblad. 152:16–18.
- Holler JM, Bosy TZ, Dunkley CS, Levine B, Past MR, Jacobs A. 2008. Delta9-tetrahydrocannabinol content of commercially available hemp products. J Anal Toxicol. 32(6):428–432. doi:10.1093/jat/32.6.428.
- Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. 2019. Cannabidiol adverse effects and toxicity. Curr Neuropharmacol. 17(10):974–989. doi:10.2174/1570159X17666190603171901.
- Jadoon KA, Tan GD, O’Sullivan SE. 2017. A single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study. JCI Insight. 2(12):e93760. doi:10.1172/jci.insight.93760.
- Johansson E, Norén K, Sjövall J, Halldin MM. 1989. Determination of delta 1-tetrahydrocannabinol in human fat biopsies from marihuana users by gas chromatography-mass spectrometry. Biomed Chromatogr. 3(1):35–38. doi:10.1002/bmc.1130030109.
- Lattanzi S, Brigo F, Trinka E, Zaccara G, Striano P, Del Giovane C, Silvestrini M. 2020. Adjunctive cannabidiol in patients with Dravet syndrome: a systematic review and meta-analysis of efficacy and safety. CNS Drugs. 34(3):229–241. doi:10.1007/s40263-020-00708-6.
- Linares IM, Zuardi AW, Pereira LC, Queiroz RH, Mechoulam R, Guimarães FS, Crippa JA. 2019. Cannabidiol presents an inverted U-shaped dose-response curve in a simulated public speaking test. Braz J Psychiatry. 41(1):9–14. https://doi.org/10.1016/s0924-977x(16)31702-3. doi:10.1590/1516-4446-2017-0015.
- Mechoulam R, Gaoni Y. 1967. The absolute configuration of Δ1-tetra-hydrocannabinol, the major active constituent of hashish. Tetrahedron Lett. 8(12):1109–1111. doi:10.1016/S0040-4039(00)90646-4.
- Mechoulam R, Shvo Y. 1963. The structure of cannabidiol. Tetrahedron. 19(12):2073–2078. doi:10.1016/0040-4020(63)85022-X.
- MHRA. 2016. Data based on Freedom of information request by Legal Foods Ltd. Results cover period of 2016 to February 2020. MHRA. Examples of determinations can be found at: final determinations made in accordance with regulation 3A of the Medicines for Human Use (Marketing Authorisations ETC.) Regulations 1994 as amended. Volume 5. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/867350/FD_List_Vol_5.pdf. Published March 2019.
- Millar SA, Stone NL, Yates AS, O’Sullivan SE. 2018. A systematic review on the pharmacokinetics of cannabidiol in humans. Front Pharmacol. 9, 1365.
- Ohlsson A, Lindgren JE, Andersson S, Agurell S, Gillespie H, Hollister LE. 1986. Single-dose kinetics of deuterium-labelled cannabidiol in man after smoking and intravenous administration. Biomed Environ Mass Spectrom. 13(2):77–83. doi:10.1002/bms.1200130206.
- Orian Research. 2018. Global cannabidiol oil (CBD oil) market research report 2018. https://www.orianresearch.com/report/global-cannabidiol-oil-cbd-oil-market-research-report-2018/464845.
- Patrician A, Versic-Bratincevic M, Mijacika T, Banic I, Marendic M, Sutlović D, Dujić Ž, Ainslie PN. 2019. Examination of a new delivery approach for oral cannabidiol in healthy subjects: a randomized, double-blinded, placebo-controlled pharmacokinetics study. Adv Ther. 36(11):3196–3210. doi:10.1007/s12325-019-01074-6.
- Pavlovic R, Panseri S, Giupponi L, Leoni V, Citti C, Cattaneo C, Cavaletto M, Giorgi A. 2019. Phytochemical and ecological analysis of two varieties of hemp (Cannabis sativa L.) grown in a mountain environment of Italian Alps. Front Plant Sci. 10:1265. doi:10.3389/fpls.2019.01265.
- Petrovic M, Debeljak Z, Kezic N, Dzidara P. 2015. Relationship between cannabinoids content and composition of fatty acids in hempseed oils. Food Chem. 170:218–225. doi:10.1016/j.foodchem.2014.08.039.
- Sawler J, Stout JM, Gardner KM, Hudson D, Vidmar J, Butler L, Page JE, Myles S. 2015. The genetic structure of marijuana and hemp. PLoS One. 10(8):e0133292. doi:10.1371/journal.pone.0133292.
- Sultan SR, Millar SA, England TJ, O’Sullivan SE. 2017. A systematic review and meta-analysis of the haemodynamic effects of cannabidiol. Front Pharmacol. 8(81), 1–13.
- The Misuse of Drugs Regulations. 2001. SI 2001/3998. http://www.legislation.gov.uk/uksi/2001/3998/made.
- Todd AR. 1946. Hashish. Experientia. 2:55–60. doi:10.1007/BF02163886.
- United Nations. 1971. Conversion on psychotropic substances. Vienna, Austria. https://www.unodc.org/pdf/convention_1971_en.pdf.
- United Nations. 1973. Commentary on the single convention on narcotic drugs, 1961. New York. https://www.unodc.org/pdf/convention_1961_en.pdf.
- United Nations. 2006. Multilingual dictionary of narcotic drugs and psychotropic substances under international control. New York (NY): United Nations. https://www.unodc.org/unodc/en/scientists/multilingual-dictionary-of-narcotic-drugs-and-psychotropic-substances-under-international-control.html.
- United Nations Economic and Social Council. 2020. Note by the Secretariat on the scope of control of substances: proposed scheduling recommendations on cannabis and cannabis-related substances. https://undocs.org/E/CN.7/2020/14. Document No: E/CN.7/2020/14
- Vandrey R, Raber JC, Raber ME, Douglass B, Miller C, Bonn-Miller MO. 2015. Cannabinoid dose and label accuracy in edible medical cannabis products. JAMA. 313(24):2491–2493. doi:10.1001/jama.2015.6613.
- Wall ME, Sadler BM, Brine D, Taylor H, Perez-Reyes M. 1983. Metabolism, disposition, and kinetics of delta-9-tetrahydrocannabinol in men and women. Clin Pharmacol Ther. 34(3):352–363. doi:10.1038/clpt.1983.179.
- World Health Organisation (WHO). 2018. Cannabidiol: critical review report. Expert committee on drug dependence fortieth meeting Geneva, 4-7 June 2018. Agenda item 4.1. https://www.who.int/medicines/access/controlled-substances/CannabidiolCriticalReview.pdf.
- Zuardi AW, Rodrigues NP, Silva AL, Bernardo SA, Hallak JEC, Guimarães FS, Crippa J. 2017. Inverted U-shaped dose-response curve of the anxiolytic effect of cannabidiol during public speaking in real life. Front Pharmacol. 8:259. doi:10.3389/fphar.2017.00259.